Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia is important to increase safety without compromising efficacy. We designed a multicenter, retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other day (QOD; N=216) and a reduced dose of 30 mg QOD (N=66) in subjects failing to have benefited from other tyrosine kinase inhibitors. The cohorts were similar with regard to baseline co-variates and adjusted for by propensity score matching. There were no significant differences in cytogenetic and molecular responses, or in outcomes between the two dose cohorts. However, the proportion of subjects receiving the original olverembatinib dose at the last follow-up was significantly higher in the 30 mg cohort: 64% (95% confidence interval [95% CI]: 53-75%) versus 44% (95% CI: 37-51%; P=0.004). Furthermore, the proportion of subjects receiving a reduced dose or permanently discontinuing because of adverse events was significantly lower in the 30 mg cohort: 21% (95% CI: 9-33%) versus 41% (95% CI: 34-48%; P=0.003). In summary, a starting dose of olverembatinib 30 mg QOD is as effective as a 40 mg starting dose but better tolerated in people with chronic phase chronic myeloid leukemia in whom other tyrosine kinase inhibitors have failed.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2025-04-30
DOI
https://doi.org/10.3324/haematol.2024.287116
Citations
3
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
5.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

Yuxia Zhao, Xiaoshuai Zhang, Linhua Yang, Jianyu Weng et al.
3 citations
Haematologica
Chronic Myeloid Leukemia Treatments
5.31
article

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

Yuxia Zhao, Xiaoshuai Zhang, Linhua Yang, Jianyu Weng, Zhenfang Liu, Zongru Li, Huanling Zhu, Shasha Zhao, Xinlong Du, Yu Zhu, Yanping Ma, Na Gao, Robert Peter Gale, Guohui Li, Lu Yu, Xiaodong Wang, Yanli Zhang, Yanqing Zhang, Li Zhou, Wen Qin, Yunfan Yang, Xin Du, Yan Wen, Bingcheng Liu, Li Meng, Qian Jiang, Lijie Yang, Jian Huang, Xuehong Ran, Yanqiu Han, Baohong Wang
article en
3 citations

Abstract

Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia is important to increase safety without compromising efficacy. We designed a multicenter, retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other day (QOD; N=216) and a reduced dose of 30 mg QOD (N=66) in subjects failing to have benefited from other tyrosine kinase inhibitors. The cohorts were similar with regard to baseline co-variates and adjusted for by propensity score matching. There were no significant differences in cytogenetic and molecular responses, or in outcomes between the two dose cohorts. However, the proportion of subjects receiving the original olverembatinib dose at the last follow-up was significantly higher in the 30 mg cohort: 64% (95% confidence interval [95% CI]: 53-75%) versus 44% (95% CI: 37-51%; P=0.004). Furthermore, the proportion of subjects receiving a reduced dose or permanently discontinuing because of adverse events was significantly lower in the 30 mg cohort: 21% (95% CI: 9-33%) versus 41% (95% CI: 34-48%; P=0.003). In summary, a starting dose of olverembatinib 30 mg QOD is as effective as a 40 mg starting dose but better tolerated in people with chronic phase chronic myeloid leukemia in whom other tyrosine kinase inhibitors have failed.

HaematologicaVol. 110(12)
Kunming University of Science and Technology (CN), Binzhou Medical University (CN), Shandong University of Aeronautics (CN), Army Medical University (CN), Guangxi Medical University (CN), Shanxi Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Sichuan University (CN), Kunming Medical University (CN), West China Hospital of Sichuan University (CN), First People's Hospital of Yunnan Province (CN), Second Affiliated Hospital of Inner Mongolia Medical University (CN), Weifang People's Hospital (CN), The First Hospital of Kunming (CN), Xinqiao Hospital (CN), First Affiliated Hospital of Kunming Medical University (CN), Peking University People's Hospital (CN), Inner Mongolia People's Hospital (CN), First Affiliated Hospital of GuangXi Medical University (CN), National Clinical Research (US), Inner Mongolia Medical College Hospital (CN), Second Hospital of Shanxi Medical University (CN), Southern Medical University Shenzhen Hospital (CN), Guangdong Academy of Medical Sciences (CN), Institute of Hematology & Blood Diseases Hospital (CN), Centre for Inflammation Research (GB), Jiangsu Province Hospital (CN), Tongji Hospital (CN), First Affiliated Hospital Zhejiang University (CN), Inner Mongolia Medical University (CN), Imperial College London (GB), Nanjing Medical University (CN)
National Institute for Health and Care Research, National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 5%
Chronic Myeloid Leukemia Treatments
5.31
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.